Current review
Low molecular weight heparins: Promising therapy for unstable angina and non-Q wave myocardial infarction

https://doi.org/10.1016/S1328-0163(97)90025-7Get rights and content

Abstract

The limitations of heparin have resulted in development of several novel anticoagulant agents for patients with acute coronary syndromes. Of these, low molecular weight (LMW) heparins are emerging as more reliable and efficacious alternatives. There may be significant differences between different LMW heparins; this awaits confirmation in ongoing clinical trials.

References (33)

  • Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary syndromes

    Lancet

    (1988)
  • P. Theroux et al.

    Aspirin, heparin, or both to treat acute unstable angina

    N Engl J Med

    (1988)
  • J.A. Cairns et al.

    Aspirin, sulphinpyrizone, or both in unstable angina

    N Engl J Med

    (1985)
  • M. Cohen et al.

    Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial

    Circulation

    (1994)
  • J.I. Weitz et al.

    Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-dependent inhibitors

    J Clin Invest

    (1990)
  • P.J. Hogg et al.

    Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy

    • View full text
    Copyright © 1997 Published by Elsevier Ltd. on behalf of The Australasian Society of Cardiac and Thoracic Surgeons and The Cardiac Society of Australia and New Zealand